Fair Value Measurements - Milestone Asset and Milestone Contingent Consideration (Details) - USD ($) $ in Thousands	12 Months Ended
Dec. 31, 2024	Apr. 03, 2024
Fair Value Measurements
Exarafenib milestone asset (Note 4)	$ 3,214
Exarafenib milestone contingent consideration (Note 4)	3,214
Kinnate CVR holders \| CVR Agreement
Fair Value Measurements
Exarafenib milestone asset (Note 4)	3,200	$ 2,900
Exarafenib milestone contingent consideration (Note 4)	3,200	$ 2,900
Increase in Exarafenib milestone asset	300
Increase in Exarafenib milestone contingent consideration	$ 300

Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

+ Details

Name:	us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase (decrease) in the value during the period from contingent consideration liability.

+ References

No definition available.

+ Details

Name:	xoma_AssetAcquisitionContingentConsiderationLiabilityChangeInAmount
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of increase (decrease) in the value during the period of milestone assets. Amount represents initial fair value in accordance with ASC 825.

+ References

No definition available.

+ Details

Name:	xoma_MilestoneAssetsIncreaseDecrease
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825.

+ References

No definition available.

+ Details

Name:	xoma_MilestoneAssetsNoncurrent
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=xoma_KinnateCvrHoldersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=xoma_ContingentValueRightsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: